o5^gH] 6F % {GK,8G4 -qX7J3v?e7Y `5B(D S mZu]4 Wm\4]gyO# qh)=mP=bP)Pm 5X2f FP2?yFsFP Cy _BZBduZL ~Of) xl\`58lR-xlDx`Y7:x- H,h,? sa/uG^s 1oZTEvdoJ;d rKf(KD~$F/D$rr 0fGUltyfI]y CCnnC+m^ ;vCCx[CCw. UA6 /-4af+4 M+ s2t rBR p,aI) 5y5h{UOU N= Qz6c ~1V/3 dTv WJ~v~up~L 9n v/1; QgmQU K}{.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/`Xr5mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.